
Performance · Recovery · Longevity
Catalogue
Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).
Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.
BPC-157 + TB-500 (UPA Platinum)
|
Category: |
Recovery / Tissue |
|
SKU: |
TRW-BPCTB |
|
Price: |
R 850.00 |
|
{{variant.name}}:
|
{{opt.name}}
{{opt.name}}
|
TEST RUN WELLNESS BPC-157 + TB-500 10 | 10mg Wolverine Stack (BPC-157 / TB-500 Hybrid Blend)
BPC-157 + TB-500 10 mg – The Wolverine Stack. A 10 mg dual-peptide blend engineered for rapid soft-tissue, tendon, ligament, and muscle repair, with deep-tissue anti-inflammatory control, restored blood supply to injured structures, and full-spectrum gut and mucosal support. Two complementary repair mechanisms in one vial, at one daily injection.
Product Overview
Test Run Wellness BPC-157 + TB-500 10 is a hybrid blend combining the two most researched repair peptides available, in a single 10mg lyophilised vial. The pairing is the most widely used recovery stack in peptide practice, and it is popular for one specific reason: the two compounds act at different points in the healing cascade, so their combined effect is greater than either delivers alone.
BPC-157 is a synthetic pentadecapeptide — the "Body Protection Compound" — derived from a partial sequence of a protein naturally present in human gastric juice. It acts on vascular supply, growth factor receptor expression and the nitric oxide system, driving new blood vessel formation at the injury site and protecting mucosal and connective tissue from inflammatory damage.
TB-500 is a synthetic fragment of thymosin beta-4, one of the most abundant actin-binding proteins in the human body. It regulates G-actin to govern cell motility, mobilising repair cells to the site of injury, and it contributes its own angiogenic and anti-fibrotic activity through the Ac-SDKP fragment.
The blend ratio is 1:1 — 5mg BPC-157 with 5mg TB-500 per 10mg vial. That ratio is deliberate: it allows the two peptides to be dosed together at matched levels across every tier of the protocol, from light post-injury maintenance through to the aggressive loading doses used for chronic and deep-tissue injury. Reconstituting the full vial with 2 ml bacteriostatic water yields 5mg/ml total blend, or 2.5mg/ml of each peptide.
The practical advantage is administration. Rather than running two separate vials, two separate reconstructions and two separate injection schedules, one reconstituted vial delivers both mechanisms in a single daily draw — which matters over a 4–6 week cycle.
How the Wolverine Stack Works: Dual Mechanism of Action
The two peptides in this blend operate on separate, complementary pathways. Understanding where each one acts explains why the combination is used rather than either compound alone.
BPC-157 works on supply and protection. Its primary action is activation of VEGFR2 and the downstream Akt–eNOS pathway, which produces endothelial cell migration, proliferation and the formation of new capillaries.
Tendon–bone junctions and ligament insertions are characteristically hypovascular — they heal slowly precisely because blood supply is poor — so restoring perfusion to those sites is a precondition for repair rather than a secondary benefit. In parallel, BPC-157 upregulates growth factor receptor expression in tendon fibroblasts, increasing local responsiveness to endogenous growth factors, and modulates the nitric oxide system, FAK–paxillin and ERK pathways involved in fibroblast migration.
Its gastrointestinal activity is a separate and unusually well-documented profile: protection against induced gastric and duodenal lesions, accelerated mucosal healing and reduced intestinal inflammation, mediated in part through NO system and dopaminergic interaction.
TB-500 works on mobilisation and remodelling. By sequestering G-actin — the monomeric building block of the cytoskeleton — it controls the polymerisation and depolymerisation cycle that drives cell movement. This is what enables endothelial cells, keratinocytes, fibroblasts and inflammatory cells to migrate toward damaged tissue.
TB-500 contributes its own angiogenic activity by stimulating endothelial cell differentiation into new capillary structures, protects cells from apoptosis under stress, and reduces inflammatory cell infiltration and pro-inflammatory cytokine expression. Its Ac-SDKP fragment adds documented anti-fibrotic activity, limiting the deposition of excess, disorganised collagen that produces scar tissue and adhesions.
The complementarity is the point. BPC-157 restores the vascular supply and protects the tissue environment; TB-500 mobilises the cells that perform repair and governs the quality of the collagen laid down. Blood supply without migrating repair cells achieves little, and migrating cells without perfusion cannot sustain the work. Combined, the blend covers site preparation, cell recruitment, matrix deposition and inflammatory control in a single protocol — and it is that full coverage, not merely two peptides in one vial, that defines the Wolverine Stack.
Body Recomposition Benefits
The Wolverine Stack's benefits are reparative and recovery-focused. It protects training continuity and improves the quality of healed tissue; it is not a muscle-building agent, has no activity at the androgen receptor, and does not directly alter body composition.
In research models, the two peptides have been used to study accelerated healing across the tissue types that most commonly cause training downtime.
In tendon and ligament, the combination addresses both the vascular deficit and the cellular recruitment required for repair, and is reported to restore tensile quality and organisation to damaged tendon and ligament tissue.
In muscle, it is used to study accelerated restoration of contractile function after induced injury, with reduced fibrosis and improved fibre regeneration. Both peptides have separately documented angiogenic activity, and together they support the restoration of blood supply on which every remodelling process depends.
Joint support and inflammation control is the second major application. The combination is used for pronounced reduction of articular pain and localised swelling, with BPC-157's reported anti-inflammatory activity against both acute and chronic inflammatory injury complemented by TB-500's reduction of inflammatory cell infiltration.
Gastrointestinal and gut repair is the third, and here BPC-157 carries the load. Its record in gastric mucosal protection is among the widest of any peptide: protection against ethanol-, NSAID- and stress-induced ulceration, acceleration of ulcer and anastomosis healing, reduced intestinal inflammation and reported benefit in colitis and short-bowel models. Improved gut integrity contributes indirectly to body composition through nutrient tolerance and absorption, and is relevant to anyone whose training and eating capacity is limited by digestive discomfort.
Recovery from acute and chronic injury is the fourth. The protocol is structured to serve both ends of the spectrum — from a single muscle strain or flare of tendinitis through to long-standing, poorly healing injury that has not responded to rest.
The anti-fibrotic contribution deserves separate mention because its effect is functional rather than cosmetic. Tissue that heals with excessive scar collagen is weaker, less flexible and more prone to re-injury than tissue that heals with organised collagen. Limiting fibrosis means the repaired structure performs closer to its original capacity once return to training is achieved.
Applied in practice, the intended benefit is a shortened time-to-return and better quality of healed tissue — the value being measured in training weeks not lost rather than in a direct performance increase.
Titration Protocol
BPC-157 + TB-500 10 is administered via subcutaneous injection, once daily. The protocol is titrated by injury severity, stepping from light post-injury support through to deep-tissue loading, with each tier delivering matched doses of both peptides.
A standard titration schedule is as follows:
· Maintenance / General: 1 mg total daily (0.5 mg BPC-157 + 0.5 mg TB-500) — light post-injury support
· Moderate / Joint Pain: 2 mg total daily (1 mg BPC-157 + 1 mg TB-500) — standard healing protocol
· Severe / Chronic Injury: 3–4 mg total daily (1.5–2 mg BPC-157 + 1.5–2 mg TB-500) — deep tissue recovery
· Cycle example: Weeks 1–4 at 2 mg daily, Weeks 5–6 at 1 mg daily, followed by a 2–4 week break before repeat cycling. Volume figures assume reconstitution of the full 10 mg vial with 2 ml bacteriostatic water, giving 5 mg/ml total blend. At that concentration, 1 mg is 0.20 ml, 2 mg is 0.40 ml, 3 mg is 0.60 ml, and 4 mg is 0.80 ml.
The tiered structure is deliberate. Begin at the maintenance tier to establish tolerability, step to the moderate tier for standard healing work, and reserve the severe tier for injury that is chronic, deep, or multi-site.
The cycle example given above — four weeks at the working dose, then a two-week taper to the maintenance tier — is a sensible structure because it allows the repair process to consolidate before the compounds are withdrawn, rather than stopping abruptly at peak dose.
Inject once daily, ideally post-training or in the morning. Post-training administration aligns dosing with the period of highest repair demand; morning administration suits users who prefer a consistent daily routine, and the extended cycle length makes routine adherence the more important variable.
Subcutaneous administration into abdominal or thigh fat is standard. For localised injury, injection into the subcutaneous tissue as close to the affected structure as is anatomically reasonable is the conventional approach; abdominal injection is used for systemic and gastrointestinal protocols. Rotate sites between abdomen, thigh and upper arm, and do not inject into an acutely inflamed, infected or recently operated area.
Reconstitute with bacteriostatic water by directing the diluent down the inside wall of the vial, then swirl gently — do not shake, to avoid denaturing the peptides. Use a new insulin or 0.5-inch needle per injection and disinfect the vial septum and injection site with an alcohol swab. Inject at a 45–90° angle into pinched subcutaneous tissue. Store the vial away from light, refrigerated at 2–8 °C, and store the reconstituted solution the same way. Do not freeze after reconstitution.
Dose escalation should only proceed if the current tier is well tolerated. Both peptides work on a timescale of weeks rather than hours, so complete a working phase before concluding that a dose level is insufficient. Follow each cycle with the full break before repeating — do not run consecutive cycles back to back.
Combination Therapy
The Wolverine Stack is itself a combination product, and it is usually deployed as the repair foundation of a broader protocol:
· Wolverine Stack + GHK-Cu 100: Extends the repair focus into dermal collagen and connective tissue quality. GHK-Cu supplies the copper-dependent collagen cross-linking and gene-modulation signal while the blend contributes vascular supply, cell migration and anti-fibrotic activity — well suited to skin quality and post-procedure recovery alongside deeper soft-tissue work.
· Wolverine Stack + GH secretagogues (CJC-1295 with or without DAC, ipamorelin): The rationale is that elevated pulsatile GH and IGF-1 raise systemic collagen synthesis and provide anabolic substrate while the blend restores blood supply and mobilises repair cells at the injured structure. Frequently used together in recovery-focused body recomposition protocols.
· Wolverine Stack + MOTS-c: Directed at the metabolic side of recovery — mitochondrial efficiency, AMPK activation and fat oxidation — alongside structural tissue repair. A popular pairing for body recomposition with concurrent injury recovery.
· Wolverine Stack + GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide): The theoretical rationale is lean-mass preservation during caloric deficit. Aggressive fat loss risks loss of lean tissue; a repair-oriented protocol supports the connective tissue and recovery capacity needed to maintain training quality while in deficit. Used under supervision, with attention to adequate protein intake.
· Wolverine Stack + graded rehabilitation: The single most important combination. Repaired tissue requires mechanical stimulus to organise along lines of stress, and without progressive loading the remodelling benefit is not fully realised. Physiotherapy and structured return-to-load should run alongside the protocol, not after it.
· Compounds that should not be assumed compatible: No interaction studies exist between these peptides and anticoagulants, antiplatelets, NSAIDs, corticosteroids or immunosuppressants. Both compounds have documented activity in vascular tissue and the nitric oxide system, and TB-500's parent protein has documented roles in cardiac and vascular tissue; concurrent anticoagulant or antiplatelet therapy warrants explicit clinical review before use. Corticosteroid injection at the same anatomical site conflicts with the protocol's intent and is generally discouraged concurrently.
All combination approaches should be pursued under professional medical supervision.
Clinical Trial Record
The Wolverine Stack pairs the two peptides with the deepest research foundations in soft-tissue repair, and each brings a distinct body of work to the combination.
BPC-157's record is broad and heavily gastrointestinal and musculoskeletal. Rodent studies of induced Achilles tendon, medial collateral ligament and patellar tendon transection report accelerated healing and improved biomechanical strength, typically at doses in the region of 10 mcg/kg daily; these tendon models form the strongest and most reproducible part of its literature. Muscle crush and transection models show accelerated functional recovery with reduced haematoma and oedema.
The largest volume of work concerns the gastrointestinal tract: protection against ethanol-, NSAID- and stress-induced gastric and duodenal lesions, accelerated ulcer and anastomosis healing, and reported benefit in colitis and short-bowel models.
Joint and cartilage models describe reduced swelling and preserved cartilage architecture, and in vitro work has demonstrated endothelial tube formation, fibroblast migration and VEGFR2/eNOS pathway activation in cell culture.
TB-500's foundation is thymosin beta-4, one of the most extensively characterised repair molecules in the literature, with a research record spanning more than four decades.
Thymosin beta-4 was identified as the principal G-actin sequestering peptide in mammalian cells, establishing the actin-regulation mechanism that governs cell motility, and its release from platelets and white blood cells at wound sites, its upregulation in healing tissue, and its angiogenic, anti-apoptotic and anti-inflammatory activities have been documented across independent research groups. The Ac-SDKP fragment's anti-fibrotic activity has its own substantial body of research.
Tissue-specific work covers dermal wound healing with reported acceleration of wound closure and improved scar outcomes, corneal epithelial repair, cardiac tissue — where the parent protein has been reported to promote cell survival and reduce scar formation after injury — and tendon, ligament and muscle repair. TB-500 also has a long-established veterinary record in performance horses for tendon and ligament injuries, an application directly relevant to human tendinopathy because equine superficial digital flexor tendon injury is one of its closest naturally occurring analogues.
Applied together, the combination's human record should be understood clearly. The two peptides are used together in practice on the strength of their complementary mechanisms and the depth of their individual preclinical and veterinary foundations.
Controlled human trials have not directly compared the combination against either peptide alone, and human outcome data for both compounds derive primarily from mechanistic, preclinical and veterinary research rather than from large randomised controlled human studies.
Their combined use rests on the mechanistic complementarity described above — supply, protection, cell recruitment and matrix quality covered in one protocol — rather than on head-to-head human trial confirmation.
Technical Specifications
· Product Name: BPC-157 + TB-500 10 (Wolverine Stack)
· Peptides: BPC-157 (pentadecapeptide) and TB-500 (thymosin beta-4 fragment), 1:1 ratio
· Concentration: 10mg blend per vial (5mg BPC-157 + 5mg TB-500)
· Form: Hybrid blend — lyophilised peptide powder, self-mix vial
· Reconstitution: Requires bacteriostatic water for reconstitution (2ml included)
· Reconstituted concentration: 5mg/ml total blend; 2.5mg/ml of each peptide
· Administration: Subcutaneous injection, once daily
· Preferred timing: Post-training or morning
· Cycle length: 4–6 weeks, followed by a 2–4 week break before repeat cycling
· Storage: Away from light, refrigerated at 2–8 °C; do not freeze after reconstitution
· Presentation: Single 10mg hybrid vial — one daily injection delivers both mechanisms
· Supplier: Test Run Wellness (Wellness.testrun)
⚕️ Important Medical Notice
Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. This peptide blend is intended for use under professional medical supervision.
Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.